Focused On-demand Library for Bardet-Biedl syndrome 1 protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NFJ9

UPID:

BBS1_HUMAN

Alternative names:

BBS2-like protein 2

Alternative UPACC:

Q8NFJ9; Q32MM9; Q32MN0; Q96SN4

Background:

The Bardet-Biedl syndrome 1 protein, also known as BBS2-like protein 2, plays a pivotal role in ciliogenesis and the sorting of specific membrane proteins to the primary cilia. It is part of the BBSome complex, essential for the formation of cilia and for the sonic hedgehog (SHH) pathway regulation. This protein's function is crucial in olfactory cilium biogenesis and maintenance.

Therapeutic significance:

Given its involvement in Bardet-Biedl syndrome 1, characterized by severe pigmentary retinopathy, obesity, and other systemic manifestations, understanding the Bardet-Biedl syndrome 1 protein could open doors to potential therapeutic strategies for this autosomal recessive disorder.